Information  X 
Enter a valid email address

Shield Therapeutics (STX)


Monday 22 March, 2021

Shield Therapeutics

Shield appoints new Chief Financial Officer

RNS Number : 9373S
Shield Therapeutics PLC
22 March 2021


Shield Therapeutics plc

("Shield Therapeutics" or the "Company")


Shield appoints new Chief Financial Officer


London, UK, 22 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), announces that Hans-Peter Rudolf is joining Shield's Senior Executive Team as Chief Financial Officer with immediate effect.


Hans-Peter is a Swiss national with extensive international experience, particularly in the US.  Starting his studies at the University of Zurich and graduating from Cleveland State University, Ohio,  Hans-Peter is a US Certified Public Accountant (CPA).  He began his career in 1991 in public practice with Deloitte in Cleveland, Ohio, before moving back to Switzerland in 1996 to join Ernst & Young (EY) where he became a partner in 2001.  In 2003 he moved back to Cleveland with EY, as an audit partner in the Cleveland office, and then between 2006 to 2010 as an audit partner with Crowe Horwath (now Crowe), the 8th largest global accounting network.  In 2011 Hans-Peter left public practice to become Head of Group Accounting at COFRA Group, a privately held Swiss conglomerate with activities in retail, real estate and investment, employing over 50,000 people worldwide. In 2017, he was appointed as Chief Financial Officer at Vicarius Pharma, a start-up company offering research-driven pharma and biotech companies a platform to build a dedicated European commercial organisation to market and sell their assets through long-term license and partnership agreements.


Tim Watts, CEO, said: "I am delighted that Hans-Peter has agreed to join Shield at this point in the Group's evolution.  His experience in both public practice and commercial companies and his US experience will be invaluable to Shield, particularly as we scale up activities in the US."


Hans-Peter said: "I am honoured to join Shield's leadership team at this exciting moment and lead its finance organization to contribute to Shield's future success as the Group progresses to the next phase of its strategy."



For further information, please contact:


Shield Therapeutics plc

+44 (0) 191 511 8500

Tim Watts (CEO)

Nominated Adviser and Joint Broker

Peel Hunt LLP

  +44 (0) 20 7148 8900

James Steel / Christopher Golden

Joint Broker

finnCap Ltd

  +44 (0) 20 7220 0500

Geoff Nash / Matthew Radley/ Alice Lane

Walbrook PR - Financial PR & IR Adviser

+44 (0) 20 7933 8780

Paul McManus / Lianne Cawthorne


or [email protected]

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol) ®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t